Vivaldi Capital Management’s Indaptus Therapeutics INDP Stock Holding History

Vivaldi Capital Management’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-857	Closed	-$13.2K	–	300
2025 Q1	$13.2K	Hold	857	–	–	﹤0.01%	283
2024 Q4	$22.2K	Hold	857	–	–	﹤0.01%	285
2024 Q3	$29.8K	Hold	857	–	–	0.01%	225
2024 Q2	$50.9K	Hold	857	–	–	0.01%	229
2024 Q1	$51.6K	Hold	857	–	–	0.02%	220
2023 Q4	$40K	Hold	857	–	–	0.01%	218
2023 Q3	$66.1K	Hold	857	–	–	0.02%	191
2023 Q2	$45.8K	Hold	857	–	–	0.01%	198
2023 Q1	$44.4K	Hold	857	–	–	0.01%	199
2022 Q4	$38.4K	Hold	857	–	–	0.01%	240
2022 Q3	$48K	Hold	857	–	–	0.01%	219
2022 Q2	$63K	Hold	857	–	–	0.02%	215
2022 Q1	$60K	Buy	+857	New	+$110K	0.02%	212

Other funds holding INDP

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Vivaldi Capital Management's INDP Position: Q2 2025 in Review

Vivaldi Capital Management sold out of Indaptus Therapeutics (INDP) in Q2 2025, closing a stake of 857 shares — an estimated $13.2K sold.

Vivaldi Capital Management first reported a position in INDP in Q1 2022 and held it in 13 quarters. The position peaked at $66.1K in Q3 2023. 5 funds tracked by Wall St. Rank hold INDP as of Q2 2025.

Vivaldi Capital Management reported no remaining Indaptus Therapeutics position as of Q2 2025 after selling out during the quarter.
Vivaldi Capital Management sold 857 Indaptus Therapeutics shares in Q2 2025, an estimated $13.2K.
Vivaldi Capital Management first reported a position in Indaptus Therapeutics in Q1 2022 and held it in 13 quarters.
Vivaldi Capital Management's Indaptus Therapeutics position peaked at $66.1K in Q3 2023.
5 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2025.

Based on Vivaldi Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.